We're so glad you're here! This site is to help anyone diagnosed with Medullary Thyroid Cancer and their caregivers find valuable information and support. If you'd like to connect with others with MTC, please consider joining our very active Facebook Group. You don't have to go through this alone!
If you don't yet have a copy, please download the American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, aka "The Guidelines." This is the MTC Bible. Read it and know it and it will help you and your doctor ensure you get the proper treatment.
Lastly, please consider looking into being seen by an MTC expert. We do our best to keep a running list of what we call "Centers of Excellence." These are doctors and facilities that are properly trained and experienced enough to treat MTC patients. It's one of the most important decisions you can make on your journey.
"Selpercatinib (Retevmo), a selective oral RET inhibitor, demonstrated durable antitumor activity and a manageable safety profile in pediatric and ..."
"These data support the ongoing Phase 3 clinical trial of olomorasib in first-line KRAS G12C-mutant lung cancer. Retevmo (selpercatinib; RET kinase ..."
"Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 · News ..."
"Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026. The pooled ..."
"Among the 36 patients, 15 had RET-altered medullary thyroid cancer (MTC), 15 had RET fusionpositive papillary thyroid cancer (PTC), and 6 had other ..."
This website is intended for educational purposes only. It is not intended, nor should it be interpreted, as medical advice or instructions of any kind. Readers are advised to consult their own medical doctor(s) for all matters involving their health and medical care.